SCHEMBL2018946

SCHEMBL2018946

O=C(Nc1ccc(F)cc1)c1cccc(Nc2ncnc3[nH]cc(C(=O)c4ccccc4)c23)c1

nearest known ligand 0.55

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
BTK Q06187 12/20 0.55
AURKB Q96GD4 3/20 0.48
EGFR P00533 2/20 0.48
INCENP Q9NQS7 1/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
SYK P43405 1/20 0.46
AURKA O14965 1/20 0.45
RPS6KB1 P23443 1/20 0.45
BRAF P15056 1/20 0.45
TNNI3K Q59H18 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2019641 0.94 BTK (0.60) BTKAURKBEGFRINCENPAURKA
SCHEMBL2024249 0.91 BTK (0.55) BTKAURKBEGFRINCENPMEN1
SCHEMBL12490856 0.88 BTK (0.59) BTKAURKBEGFRINCENPAURKA
SCHEMBL12495300 0.87 AURKB (0.61) BTKAURKBEGFRINCENPMEN1
SCHEMBL2018889 0.86 BTK (0.54) BTKEGFRBRAFTNNI3K
SCHEMBL2020684 0.85 BTK (0.53) BTKMEN1KMT2ANPC1RAB9A
SCHEMBL2019287 0.85 EGFR (0.59) BTKEGFRBRAFTNNI3K
SCHEMBL2016793 0.85 BTK (0.49) BTKBRAFTNNI3K
SCHEMBL2021279 0.84 BTK (0.53) BTKEGFRBRAFTNNI3K
SCHEMBL2022024 0.84 BTK (0.50) BTKAURKBEGFRINCENP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8580803-B2 Substituted pyrrolo-aminopyrimidine compounds ARQULE, INC. (US) 2013-11-12 US disclosed
US-8580803-B2 Substituted pyrrolo-aminopyrimidine compounds ARQULE, INC. (US) 2013-11-12 US disclosed
US-8580803-B2 Substituted pyrrolo-aminopyrimidine compounds ARQULE, INC. (US) 2013-11-12 US disclosed
WO-2011082273-A2 SUBSTITUTED PYRROLO-AMINOPYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2011-07-07 WO disclosed
US-20110160203-A1 Substituted Pyrrolo-Aminopyrimidine Compounds ARQULE, INC. (US) 2011-06-30 US disclosed
US-20110160203-A1 Substituted Pyrrolo-Aminopyrimidine Compounds ARQULE, INC. (US) 2011-06-30 US disclosed
US-20110160203-A1 Substituted Pyrrolo-Aminopyrimidine Compounds ARQULE, INC. (US) 2011-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160203-A1 Substituted Pyrrolo-Aminopyrimidine Compounds DPYD, TYMP, DHFR BTK 1600/4885AURKB 295/4885EGFR 1215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.